» Articles » PMID: 20702618

Ultrastructural Analysis of ICP34.5- Herpes Simplex Virus 1 Replication in Mouse Brain Cells in Vivo

Overview
Journal J Virol
Date 2010 Aug 13
PMID 20702618
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Replication-competent forms of herpes simplex virus 1 (HSV-1) defective in the viral neurovirulence factor infected cell protein 34.5 (ICP34.5) are under investigation for use in the therapeutic treatment of cancer. In mouse models, intratumoral injection of ICP34.5-defective oncolytic HSVs (oHSVs) has resulted in the infection and lysis of tumor cells, an associated decrease in tumor size, and increased survival times. The ability of these oHSVs to infect and lyse cells is frequently characterized as exclusive to or selective for tumor cells. However, the extent to which ICP34.5-deficient HSV-1 replicates in and may be neurotoxic to normal brain cell types in vivo is poorly understood. Here we report that HSV-1 defective in ICP34.5 expression is capable of establishing a productive infection in at least one normal mouse brain cell type. We show that γ34.5 deletion viruses replicate productively in and induce cellular damage in infected ependymal cells. Further evaluation of the effects of oHSVs on normal brain cells in animal models is needed to enhance our understanding of the risks associated with the use of current and future oHSVs in the brains of clinical trial subjects and to provide information that can be used to create improved oHSVs for future use.

Citing Articles

Ependymal cells: roles in central nervous system infections and therapeutic application.

Xie S, Li F J Neuroinflammation. 2024; 21(1):255.

PMID: 39385253 PMC: 11465851. DOI: 10.1186/s12974-024-03240-2.


Role of Herpes Simplex Virus 1 γ34.5 in the Regulation of IRF3 Signaling.

Manivanh R, Mehrbach J, Knipe D, Leib D J Virol. 2017; 91(23).

PMID: 28904192 PMC: 5686731. DOI: 10.1128/JVI.01156-17.


Pre-clinical Assessment of C134, a Chimeric Oncolytic Herpes Simplex Virus, in Mice and Non-human Primates.

Cassady K, Bauer D, Roth J, Chambers M, Shoeb T, Coleman J Mol Ther Oncolytics. 2017; 5:1-10.

PMID: 28345027 PMC: 5363760. DOI: 10.1016/j.omto.2017.02.001.


Pancreatic cancer gene therapy: from molecular targets to delivery systems.

Fillat C, Jose A, Bofill-Deros X, Mato-Berciano A, Maliandi M, Sobrevals L Cancers (Basel). 2013; 3(1):368-95.

PMID: 24212620 PMC: 3756366. DOI: 10.3390/cancers3010368.

References
1.
Whitley R, Kern E, Chatterjee S, Chou J, Roizman B . Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma 1 34.5 deletion mutants in rodent models. J Clin Invest. 1993; 91(6):2837-43. PMC: 443352. DOI: 10.1172/JCI116527. View

2.
Andreansky S, Soroceanu L, Flotte E, Chou J, Markert J, Gillespie G . Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res. 1997; 57(8):1502-9. View

3.
Del Bigio M . The ependyma: a protective barrier between brain and cerebrospinal fluid. Glia. 1995; 14(1):1-13. DOI: 10.1002/glia.440140102. View

4.
Mineta T, Rabkin S, Yazaki T, Hunter W, Martuza R . Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med. 1995; 1(9):938-43. DOI: 10.1038/nm0995-938. View

5.
Campadelli-Fiume G, Roizman B . The egress of herpesviruses from cells: the unanswered questions. J Virol. 2006; 80(13):6716-7. PMC: 1488928. DOI: 10.1128/JVI.00386-06. View